Thermo Fisher Scientific is acquiring Olink, a company that provides proteomics analysis tools and services used in drug discovery research. Olink’s growing revenue will help shore up a Thermo Fisher business segment whose sales have fallen due to declining Covid-19 testing demand.
Neko Health recently raised €60 million (about $65.8 million) in Series A financing. The Stockholm-based startup's medical scanning technology aims to conveniently and affordably collect extensive health data to aid doctors in catching diseases early. The company’s scan takes about 10 minutes and costs €250 (about $275).
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Sobi said it plans to seek FDA approval of the gout drug, SEL-212, in 2024. If approved, it would compete against Krystexxa, a Horizon Therapeutics drug projected to become a blockbuster seller.
A randomized, controlled study published in JAMA Open found that patients who engaged in a virtual physical therapy program saw a greater reduction in knee pain than those who continued with their usual care plan at home. However, the study was not blinded, which could affect patients' self-reported pain scores.
The Nobel Prize in Medicine or Physiology went to Drs. William Kaelin, Gregg Semenza and Peter Ratcliffe. Their research has led to new strategies for treating diseases like cancers and anemia.
On Friday, Novartis presented data at ECTRIMS showing that Arzerra had superior efficacy to Sanofi's Aubagio. Johnson & Johnson's Janssen division had presented data for its drug, ponesimod, two days before.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
In a phone interview, CEO Jakob Lindberg indicated that data so far showed a study was doing well in terms of progression-free survival.
The Swedish drugmaker acquired rights to the drug from Switzerland-based Novimmune in July for about $50 million, plus about $400 million in payments over eight years.
Sobi buys US rights to Synagis, currently the only drug approved for treating RSV, along with 50 percent of US earnings for its successor, the Phase II MEDI8897.
The challenge with radiation and other cancer therapies is getting the right amount of treatment to the tumor and leaving healthy cells unscathed.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The company will use most of the new funding to build up its sales, business development and marketing operations, with the goal of fully entering the U.S. market by the second quarter of 2017.
The deal will privatize South Bend, Indiana-based Press Ganey just 16 months after it had gone public.
Pond Healthcare Innovation CEO Daniel Taub said in an interview that the Air Smart spirometer device is CE-certified by European regulators and is available in Europe
Clinical trials are three years away for this necrotising enterocolitis treatment.
With blood donation rates continuing to decrease, initiatives to make the process more personal and social could make a big difference.